PKD inhibition decreased the tolerance to ischemia/reperfusion injury. 17 PKD expression and activity are also increased in failing rat, 7 rabbit, and human myocardium. 18 These findings indicate the importance of PKD in modulating cardiac
C ardiac remodeling occurs after various types of insults to the heart, including inflammation and pressure and volume overload. 1, 2 Associated molecular, cellular, and interstitial changes, such as re-expression of fetal genes, myocyte hypertrophy, cell death, and fibrosis, eventually become maladaptive leading to cardiac dysfunction and failure. Therapeutic strategies, therefore, often target the signaling pathways that underlie the cardiac remodeling processes. In recent years, protein kinase D (PKD) has emerged as a key signaling nodal point affecting excitation-contraction coupling (via myofilament-binding protein C, cardiac troponin I, and L-type Ca2+ channels), [3] [4] [5] [6] gene expression (via histone deacetylases 7, 8 and cAMP-response element-binding protein), 9 cell survival, [10] [11] [12] and energy substrate use. [13] [14] [15] In vivo, cardiac-specific expression of constitutively active PKD1 caused pronounced dilated cardiomyopathy, 7 whereas cardiac-specific PKD1 knockout mice proved remarkably resistant to cardiac hypertrophy and fibrosis in response to pressure overload or chronic administration of adrenergic or angiotensin receptor agonists. 16 Conversely, pathophysiology and its potential as a therapeutic target for cardiovascular disease.
Three highly homologous PKD isoforms have been identified (PKD1-3, with PKD1 predominant in the heart). 2, 19 PKDs possess substrate specificity similar to calmodulin-dependent protein kinase and structural features reminiscent of PKCs. Indeed the modular structure of PKD consists of a C-terminal catalytic domain and an N-terminal region with autoinhibitory, regulatory domains, such as the diacylglycerol-binding domain and the pleckstrin homology domain. 20, 21 Several regulatory mechanisms (eg, 22 for comprehensive review) can modulate PKD1 activity, including autoinhibition, phosphorylation, proteolytic degradation, subcellular localization, and protein interactions, resulting in complex, context-specific PKD signaling mechanisms.
The typical signaling cascade to PKD activation involves G-protein-coupled receptor-dependent activation of phospholipase C and production of diacylglycerals. The latter stimulate PKD directly and indirectly via coincident activation of PKCs, while recruiting PKD near its upstream kinase. The activation is largely dependent on phosphorylation of the activation loop residues (S744/S748 in murine numbering) by both PKC-dependent and PKC-independent mechanisms. [23] [24] [25] [26] Despite this general consensus on global PKD activation for G-protein-coupled receptor agonists, our group 27, 28 recently identified dramatic spatiotemporal differences in PKD1 activation for 2 G q -coupled agonists, phenylephrine and endothelin-1 (ET1), in adult cardiomyocytes. Although both agonists triggered comparable global PKD1 activation, phenylephrine induced fleeting sarcolemmal PKD1 translocation and activation followed by nuclear translocation and ET1 prompted persistent sarcolemmal recruitment and activity. The ability to alter the location and signal generation of PKD1 dynamically is clearly an integral part of achieving PKD signal specificity, yet this highly contextual and microdomain aspect of PKD signaling remains poorly understood.
Surprisingly, little is known about the effect of β-adrenergic receptor (β-AR)/PKA signaling on PKD function and activation in cardiomyocytes and the few existing reports are conflicting. Initial reports from the Olson group saw no effect of β-AR or PKA stimulation on PKD phosphorylation or activity. 7 Carnegie et al [29] [30] [31] later found that A-kinase anchoring protein (AKAP)-Lbc functions as a scaffold for PKA and PKC, facilitating PKD activation and the transduction of hypertrophic responses (via histone deacetylase 5 and Mef2 [myocyte enhancer factor-2]). Others, examining global PKD activity, report a counter modulatory role for PKA and PKC on PKD activation in adult myocytes, [32] [33] [34] which is an inhibitory role for PKA.
In the present study, we resolve these conflicting findings by examining local PKD translocation and activation in response to PKA signaling alone and the crosstalk between these 2 signaling kinases in adult cardiac myocytes. We find that β-AR/ PKA signaling drives nuclear activation of PKD without requiring a sarcolemmal recruitment phase. β-AR/PKA signaling also prevents Gq-coupled receptor (G q R)-induced translocation, activation, and function of PKD, and we show that these effects are mediated by PKA-dependent phosphorylation of PKD at S427. Moreover, initial observations in a transverse aortic constriction (TAC)-induced hypertrophy model indicate altered phosphorylation of this S427 site. Our study provides further evidence of compartmentalized PKD signaling and indicates how S427 could serve as a critical control point for modulation of the spatiotemporal dynamics of PKD activity and function during the pathogenesis of cardiac disease.
Methods

Cardiomyocyte Isolation and Culture
All animal and biohazard procedures were conducted in accordance with National Institutes of Health guidelines for animal research and with institutional approval. Biohazard procedures were performed in accordance with a University of California, Davis-approved Biological Use Authorization. Adult myocytes were isolated and cultured as previously described. 27, 35 Neonatal rat cardiomyocytes (NCMs) were cultured as instructed. Green fluorescent protein (GFP)-PKD-wildtype (WT) and GFP-PKD-S427E expressions were via adenoviral infection. Before experiments, myocytes were serum deprived for 24 hours by switching to DMEM with Nutridoma-SP.
Confocal, Fluorescence Resonance Energy Transfer, and Total Internal Reflection Fluorescence Measurements
All confocal and total internal reflection fluorescence (TIRF) experiments were performed as previously reported. 27 Myocytes were exposed to inhibitors for 15 to 20 minutes before and after the addition of agonists. Fluorescence resonance energy transfer was measured 27 using both a ratiometric and an acceptor photobleach approach. Background-corrected fluorescence intensities at specific cellular locations were reported as a ratio of F CFP /F YFP (normalized to initial ratio).
Immunoblotting
Cell lysates and subcellular fractions were obtained as previously described 27, 36 and probed with Cell Signaling PKD1, PKDpS916, phospho-PKA-substrate (RRXS*/T*), phospho-Akt substrate (RXXS*/T*), phospho-PKD-substrate and histone 3; Abcam GAPDH, PKDpS916, PKA, and a custom PKD pS427 antibody; Santa Cruz Biotechnology GFP and from Millipore NKAα1. Immunoreactive band intensities were quantified using ImageJ.
Immunoprecipitation
Immunoprecipitation was performed as before 37 using anti-GFP, PKD, or PKARII (protein kinase A regulatory subunit II) antibody at 4°C overnight followed by incubation with protein A/G-coupled magnetic beads for 2 hours before resuspending in sample buffer.
Sequence Alignment
Sequence alignment and analysis were performed using Geneious version 6.0.4 by Biomatters (http://www.geneious.com/).
Cellular Hypertrophy
NCMs were treated as indicated before subjecting to standard immunocytochemistry and reverse transcriptase-polymerase chain reaction of hypertrophic markers. Fixed NCM were stained for α-actinin (Sigma, 1:1000). Cell size measurements were made Nonstandard Abbreviations and Acronyms β-AR β-adrenergic receptor DKAR D-kinase activity reporter
NCMs neonatal rat cardiomyocytes TIRF total internal reflection fluorescence WT wildtype using ImageJ. Total RNA was isolated using TRIZOL Reagent and NucleoSpin RNA II, followed by quantification using Nanodrop and then Quant-iT RiboGreen. cDNA was generated from RNA with RNA-to-cDNA-EcoDry-Premix and then amplified with GoTaq qP-CRMasterMix. Custom primers (Illumina) were used for detection of each mRNA-control genes: Hmbs, Rpl13a, Hprt1, Myh6, Myh7, Acta1, Nppb, and Nppa. The threshold crossing value was noted for each transcript and normalized to internal control. The relative quantification of each was performed using the comparative Ct method.
TAC Surgery
All procedures were essentially as described. 38 TAC was performed on 8-week-old male mice around a 27-gauge needle. Sham-operated mice were subjected to identical interventions except for aortic constriction. Cardiac dysfunction was measured 3 weeks later via echocardiography. The mice were euthanized, and hearts were harvested. For cardiac homogenates, the heart was powdered and resuspended in ice-cold buffer containing (in mmol/L): 10 Na 2 HPO 4 , 150 NaCl, 5 EGTA, 5 EDTA, 5 NaF, 1 orthovanadate with 1% TritonX-100, 1% Na deoxycholate, and protease and phosphatase inhibitors. After homogenization with polytron at 5000 rpm for 20 s and 5 strokes of a Dounce homogenizer, samples were centrifuged at 5000g. Supernatants were flash-frozen.
Statistical Analysis
Pooled data are expressed as mean±SEM. Statistical discriminations were performed with Student t test and 2-way ANOVA with P<0.05 considered significant. Expanded Methods can be found in the Online Data Supplement.
Results
β-AR/PKA Drives Noncanonical PKD Translocation
Initial experiments focused on establishing whether β-AR or PKA activation alone affects PKD signaling and localization. Adult cardiomyocytes expressing GFP-PKD1 (after adenovirus infection) were monitored via confocal microscopy after 100 nmol/L isoproterenol or 10 μmol/L forskolin exposure ( Figure 1A ). Quantification of the signal at the sarcolemma versus that in the cytosol (F SL /F cyto ) showed that neither isoproterenol nor forskolin induced sarcolemmal recruitment of PKD ( Figure 1B ). This is in contrast to the pronounced sarcolemmal recruitment of PKD, we previously observed in response to the G q R-agonists: phenylephrine and ET1. 28 Notably, even without a preceding sarcolemmal translocation phase, both isoproterenol and forskolin triggered nuclear import of PKD (after 60 minutes, F nuc /F cyto was increased by 12±2% and 13±2%, respectively; F nuc contains both intranuclear and nuclear membrane fluorescence intensities). This nuclear import was also readily detectable in population studies of PKD distribution in response to isoproterenol (ie, unpaired measurements of F nuc /F cyto ; Figure 1C ). To measure sarcolemmal recruitment of PKD more selectively, we also used TIRF microscopy to assess fluorescence only within ≈100 nm of the glass coverslip-solution interface ( Figure 1D ). As in the confocal experiments, neither the β-AR agonist isoproterenol nor the direct activation of adenylyl cyclase by forskolin induced significant sarcolemmal recruitment of PKD. This suggests that β-AR/PKA activation triggers a translocation pattern that deviates from the classical PKD activation pattern of a membrane recruitment phase followed by translocation to subcellular targets, such as the nucleus.
cAMP-Dependent Signaling Selectively Activates Nuclear PKD
Using genetically encoded fluorescence resonance energy transfer-based D-kinase activity reporter (DKAR), we previously showed that the triggered PKD translocation parallels the evoked local kinase activity. 28 Because of the possibility that PKD may be activated in the absence of previous sarcolemmal translocation, we used targeted DKARs (to nucleus, cytosol, or sarcolemma) to monitor the time course and magnitude of PKD activation selectively in response to isoproterenol or forskolin. Phosphorylation of the PKD-specific substrate sequence in this biosensor results in a decrease in fluorescence resonance energy transfer (ie, an increase in cyan fluorescent protein/yellow fluorescent protein ratio). 39 Although the DKAR dynamic range is small (≈10%), they are able to detect spatiotemporal differences in PKD activation. 28 We found that exposure of adult cardiac myocytes to isoproterenol or forskolin failed to elicit any PKD activation at the sarcolemma or cytosol, measured with DKAR-MyrP (poly-myristoylated) and DKAR-NES (nuclear exclusion signal), respectively ( Figure 2A ). However, both isoproterenol and forskolin activated nuclear PKD ( Figure 2A ). The effect was more potent for forskolin, reflecting the more robust PKA activation. We confirmed these results using the acceptor photobleach method (not shown). These observations support the notion that PKA activation induces nuclear translocation and activation of PKD without a preceding sarcolemmal recruitment and activation phase.
We also used immunoblotting ( Figure 2B ) to assess global effects on PKD activity in response to β-AR or PKA. For these in vitro measurements, autophosphorylation at S916 was used as readout of PKD activity. Consistent with our previously published findings, myocyte exposure (for 20 minutes) to phorbol 12,13-dibutyrate (a phorbolester), phenylephrine, or ET1 significantly increased PKD S916 autophosphorylation when compared with untreated myocytes. In contrast, isoproterenol or forskolin treatment did not alter baseline S916 phosphorylation. The lack of an effect on global PKD autophosphorylation status may be because of the relatively minor contribution of nuclear PKD to that of the whole cell (estimated to be <3% of total PKD based on subcellular compartment estimates of total cell volume). So, fractionated mouse hearts (± isoproterenol) were analyzed for PKD activation (via pS916 signals) and phosphorylation of PKD targets (using a PKD consensus motif antibody). Although S916 and PKD target phosphorylation signals were slightly decreased in the cytosolic and sarcolemmal fractions, they were increased in the nuclear compartment (Online Figure I) . These biochemical observations confirm that β-AR signaling stimulates local, nuclear PKD signaling.
Having established the effect on PKD of β-AR/PKA signaling alone, we set out to determine how this pathway affects signaling through G q R/PKD pathways ( Figure 2B ). We found that preactivation of PKA by forskolin prevented the increase in S916 phosphorylation induced by ET1 and phenylephrine. In contrast, forskolin pretreatment failed to prevent S916 autophosphorylation in response to phorbol 12,13-dibutyrate. These results indicate that PKA-dependent signaling suppresses global PKD activation in cardiomyocytes in response to G q R-agonists, at least as sensed by S916 phosphorylation. Potent stimuli, such as the diacylglycerol analogue phorbol 12,13-dibutyrate, are still able to overcome this inhibition.
β-AR/PKA Negatively Modulates Gq-Driven PKD Translocation
Clearly, there are subcellular, compartmentalized responses to PKA-and G q R-dependent activation of PKD. To assess whether microdomain signaling plays a role in this PKA-dependent modulation of G q -coupled PKD activation, we examined PKD-GFP translocation in adult cardiomyocytes. Consistent with previous observations, confocal imaging revealed pronounced sarcolemmal translocation in response to phenylephrine and ET1 (stronger and sustained for ET1), followed by nuclear translocation, which is more rapid and prominent for phenylephrine. Isoproterenol pretreatment prevented both the ET1-and the phenylephrine-induced PKD translocation to the sarcolemma ( Figure 3B , left). F SL /F cyto at 60 minutes remained at baseline for isoproterenol-pretreated myocytes versus an increase of 9±1% and 31±4% for phenylephrine and ET1 alone. The G q R-agonist-mediated nuclear import of PKD was also blocked by preincubation with isoproterenol ( Figure 3B, right) . The phenylephrine-triggered increase in F nuc /F cyto ratio after 60 minutes was only 1±2% in isoproterenol-pretreated myocytes (versus 18±2% for phenylephrine alone). Likewise, the increase in F nuc /F cyto ratio was only 2±1% after 60 minutes of ET1 in isoproterenol-pretreated cells (13±3%). Of note, the isoproterenol-induced nuclear import had already occurred within the 15-minute pretreatment period (an ≈10% increase). This higher, new baseline (reset to 1) was used to estimate the G q R.
To corroborate our confocal findings, we used TIRF microscopy to dissect the isoproterenol-induced signaling cascade, leading to alterations in phenylephrine-/ET1-induced PKD translocation. Our TIRF measurements confirmed that β-AR activation with isoproterenol (15-minute pretreatment) prevents ET1-induced sarcolemmal recruitment of PKD in adult myocytes ( Figure 3C , top). Elevating cAMP levels with forskolin to activate PKA more directly also blocked the ET1 effects. Consistent with these observations, preincubation with 8-Rp-Br-cAMP, a cell-permeable cAMP analogue, which specifically blocks PKA activation, prevented the isoproterenol-and forskolin-dependent inhibitory effects on ET1driven PKD translocation ( Figure 3C ). Similar results were obtained for phenylephrine (Online Figure II) , even though the phenylephrine-induced sarcolemma retention of PKD is lower than for ET1. Taken together, these data indicate that signaling through a β-AR/cAMP/PKA pathway negatively regulates G q R-agonist-evoked PKD translocation. 
β-AR Signaling Negatively Modulates Local PKD Activity
Targeted DKARs ( Figure 3D ) were used in parallel studies to test how G q R-agonists affect the spatiotemporal dynamics of PKD activation after β-AR stimulation. Although ET1 and phenylephrine triggered comparable sarcolemmal PKD activity, isoproterenol pretreatment blocked ET1-or phenylephrine-induced PKD activation at the sarcolemma (Figure 3D, top) . Phenylephrine and ET1 also triggered nuclear PKD activation although to a much greater extent for phenylephrine. Isoproterenol pretreatment again effectively reduced PKD activation in the nuclear compartment in response to phenylephrine or ET1 ( Figure 3D, bottom) . Collectively, our data show that β-AR/cAMP/PKA signaling profoundly perturbs G q R-agonist-induced PKD activation and translocation in adult cardiomyocytes. Parallel subcellular fractionation experiments and probing for activated PKD (pS916) support these findings (Online Figure III) . As shown for the sarcolemmal compartment, phenylephrineand ET1-induced increase in signal is prevented by isoproterenol pretreatment.
PKA-Dependent Phosphorylation of PKD
To date, it was unclear whether the disruption of G q -induced PKD signaling is mediated via direct PKA phosphorylation of PKD or other PKA-mediated effects. So we used 2 separate PKA-consensus-motif antibodies (pRRXS*/T* and pRXXS*/T*) to test whether PKA can directly phosphorylate PKD. Western blots of purified PKD1 phosphorylated in vitro with PKA show increased immunoreactivity with both PKA-consensus-motif antibodies ( Figure 4A ). H89 inhibition of PKA strongly reduced the signals, whereas PKD inhibition with CID755673 had little effect. Thus, PKD is a PKA substrate. Moreover, PKD can be coimmunoprecipitated with the PKA regulatory subunit (Online Figure IV) in myocyte lysates. So we tested whether PKD is a PKA target in vivo. Myocytes expressing GFP-PKD were treated with isoproterenol, forskolin, or vehicle before PKD immunoprecipitation using GFP antibody and protein A/G magnetic beads. Figure  4B shows a representative immunoprecipitation probed with pRRXS*/T* and GFP antibodies. The GFP panel shows that equivalent amounts of PKD were immunoprecipitated, and the control immunoprecipitations, using beads or control immunoglobulin G ( Figure 4C) , show the specificity of the pull-down. Isoproterenol and forskolin treatment increased the pRRXS*/T* signal in the myocyte lysate (preimmunoprecipitation lanes), indicating increased PKA phosphorylation. The pRRXS*/T* signal in immunoprecipitated PKD was also increased, indicating PKA phosphorylates PKD.
Consensus PKA sites were subsequently identified throughout PKD1 with the Scansite program (http://scansite.mit.edu) to further the notion of direct PKA phosphorylation of PKD. PKD contains several potential PKA substrate sequences ( Figure 4D ), including several known auto-and transphosphorylation sites (S916, S255, S748, and S203). Among these, the sequence surrounding S426 to S427 is of particular interest because either serine residue could serve as phosphoacceptor, the sequence is entirely conserved among vertebrate species. In addition, S427 was recently identified in vitro as a potential PKA target although no link to changes in PKD localization or catalytic activity was reported. 40 
PKD-S427E Mimics the β-AR Inhibition of G q R-Induced PKD Translocation
We speculated that direct phosphorylation of PKD by PKA at this site alters PKD translocation. We used confocal microscopy ( Figure 5A ) to test whether a phosphomimetic substitution at S427 (PKD-S427E) would similarly perturb G q R-evoked PKD translocation. At baseline, this mutant had a slightly higher nuclear localization (F nuc /F cyto was 0.69±0.02 versus 0.62±0.02 for WT myocytes) but otherwise targeted like WT (Online Figure V) . Our previous findings indicate a predominantly sarcolemmal and nuclear response for ET1 and phenylephrine, respectively, so we focused our confocal analysis on the relevant compartment for each agonist. Adult myocytes expressing GFP-tagged PKD-S427E displayed severely blunted sarcolemmal recruitment in response to ET1 (versus PKD-WT; Figure 5A and 5B). ET1 application (for 60 minutes) increased F SL /F cyto by only 7±2% for the S427E mutant versus 31±4% for PKD-WT. Similarly, phenylephrine-triggered nuclear import was drastically reduced in PKD-S427E expressing myocytes versus WT. F nuc /F cyto after 60 minutes of phenylephrine was only 2±2% for PKD-S427E versus 18±2% for PKD-WT. Parallel TIRF experiments showed even more clearly that S427E substitution resulted in decreased membrane recruitment for both G q R-agonists ( Figure 5C ). Also of note, after isoproterenol treatment, F nuc /F cyto was increased (from 0.69±0.02 to 0.77±0.02, similar to WT; Online Figure V) , indicating that the β-AR-induced nuclear import of PKD does not depend on S427. However, S427E substitution does recapitulate the PKA-mediated disruption of G q R-induced PKD translocation. Moreover, pS916 measurements show that like isoproterenol pretreatment ( Figure 2B ), S427E substitution renders PKD resistant to G q R stimuli but not to robust activation with phorbol 12,13-dibutyrate (Online Figure VI) . Together, our data indicate that S427 mediates the PKA-dependent suppression of GqR-induced PKD activation and translocation.
PKD-S427 Mediates the β-AR Effects on Downstream G q R-PKD Signaling
We speculated that S427E substitution would also affect downstream G q R-induced PKD effects. So in light of the well-characterized role of PKD as a histone deacetylase kinase, we examined the effect of S427E substitution on cardiomyocyte hypertrophy. NCMs were infected with GFP-PKD-S427E, GFP-PKD-S427A, or GFP-PKD-WT. As shown in Figure 6A , the expression of PKD-S427E prevented sarcomere assembly and cell enlargement in response to phenylephrine or ET1, whereas S427A responded similar to WT. Cardiac hypertrophy is associated with reactivation of a pathological fetal gene program, such as genes encoding for atrial natriuretic peptide, brain natriuretic peptide, and α-skeletal actin. Agonist-dependent elevation of hypertrophy markers can be assessed by reverse transcriptase-polymerase chain reaction. Figure 6B shows that isoproterenol blunts phenylephrine-dependent induction of α-skeletal actin expression (left) in NCMs expressing PKD-WT. α-skeletal actin transcript induction by phenylephrine was likewise markedly reduced in the presence of PKD-S427E, indicating that S427E substitution recapitulates the β-AR effects on downstream G q R-evoked PKD signaling. Similar results were obtained for atrial natriuretic peptide, brain natriuretic peptide, and myosin 7 (Figure 6B , right; Online Figure VII ). In addition, isoproterenol was unable to suppress phenylephrine-dependent gene expression for the unphosphorylatable S427A mutant ( Figure 6B ).
Altered S427 Phosphorylation in Cardiac Disease
These data indicate that S427 is a key regulatory site on PKD, which can render the kinase resistant to G q R stimuli. Given the role of PKD in cardiac hypertrophy and heart failure development, it is therefore tempting to speculate that the phosphorylation state of this PKD control point would also change during the pathogenesis of heart failure. So we developed a custom antibody to monitor S427 phosphorylation. We verified antibody specificity using unphosphorylatable GFP-PKD1 constructs in human embryonic kidney cells. Figure 6C shows that immunoreactivity increased after forskolin treatment for WT and S426A but not for S427 and SS426/427AA, indicating this novel antibody specifically detects phosphorylation at S427. This antibody signal also increased in lysates from isoproterenol-or forskolin-treated myocytes but not in the presence of PKA inhibitors H89 or 8-Br-Rp-cAMP ( Figure 6D ). Subcellular fractionation experiments found that in response to isoproterenol, PKD pS427 signals were increased throughout the cell but particularly in the sarcolemmal compartment (Online Figure VIII) . These findings confirm that isoproterenol triggers PKA-dependent phosphorylation of S427. We then probed S427 phosphorylation in cardiac homogenates from 3-week TAC mice versus their Sham controls. Echocardiography confirmed that banded mice had significant alterations in structural and functional cardiac parameters (Online Figure IX) . Figure 6E shows that S427 phosphorylation, PKD1 expression, and S427-phosphorylated PKD1 were all increased in TAC versus Sham. These observations suggest that S427 phosphorylation could be modulated during the development of cardiac hypertrophy and heart failure and deserves further investigation.
Discussion
Here, we show for the first time that β-AR/PKA modulation triggers atypical PKD activation by inducing its nuclear activation without preceding sarcolemmal translocation. We also demonstrate that important crosstalk exists between G q R and β-AR signaling and uncover the effects of β-AR signaling on spatiotemporal regulation of PKD. Furthermore, we identify S427 as a novel regulatory phosphorylation site on PKD with a key role in tuning the spatiotemporal dynamics of PKD activity and downstream functional effects. Our study highlights the importance of local activation and regulation for a multifunctional kinase, such as PKD, to achieve its compartmentalized roles and substrate specificity.
Our data reconcile previous opposing findings of PKA-dependent facilitation 29, 30 and inhibition of PKD signaling. [32] [33] [34] We find here that β-AR/PKA activation of PKD selectively drives nuclear PKD recruitment and activation without initial translocation to the sarcolemma (Figure 1 ). This differs from the stereotypical activation mechanism. This effect was not detectable with in vitro studies, examining global PKD activation via phosphorylation alone (pS916 measurements). This is consistent with previous work using immunoblotting that found no effect of β-AR/PKA stimulation alone on PKD activity. 7, [32] [33] [34] The critical advantage of our approach is that it permits in situ monitoring of subtle differences in PKD activity within specific subcellular domains, such as the nucleus. Our observation of local, nuclear PKD activation in response to β-AR/ PKA signaling fits with reports from the Scott Laboratory 29, 30 that PKA activation amplifies PKD signaling. They proposed that AKAP-Lbc serves as a platform synchronizing PKA and PKC activities, thereby facilitating the release of activated PKD and downstream transcriptional activation. The increase in nuclear PKD (and its activity; Figure 7 , left) could originate from this AKAP-Lbc-bound pool of PKD or from another perinuclear AKAP pool (eg, mAKAP [muscle A-kinase anchoring protein]). 41 Increased PKA activity would trigger the release of activated PKD from this scaffold, permitting its movement to the nucleus without previous sarcolemmal recruitment (in this scenario PKA-dependent phosphorylation of S427 does not play a role). Therefore, specific stimuli could engage only a subset of PKD signaling pathway components that are spatially restricted to particular subcellular domains, allowing for precise fine-tuning of the functional outcome. The type of data we have obtained should lend valuable insight into the complexities of spatial and temporal regulation of PKD activity.
Aside from inducing local, nuclear PKD signaling, β-AR/ PKA stimulation was also found to prevent G q R-agonist-induced translocation and subsequent PKD activation. Our working hypothesis is that these divergent effects are achieved by modulating distinct pools of PKD in the myocyte (Figure 7) , highlighting the importance of precise spatial control of PKD activity. In addition, we provide strong evidence that PKAdependent phosphorylation of PKD at S427 is critical to β-AR-dependent modulation of G q R-induced PKD activation and function. This is because the phosphomimetic substitution (PKD-S427E) dramatically reduces G q R-induced PKD translocation and cardiac hypertrophy ( Figures 5 and 6 ). Therefore, our data resolve a long-standing question of how this striking β-AR inhibition of PKD activation by G q R-agonists occurs. Two other hypotheses had been advanced to date. First, β-AR-dependent modulation of phospholipase C could limit G q R-induced PKD activation (but see also Stangherlin et al 42 ). 33, [43] [44] [45] Second, PKA stimulation of PP2a activity may abrogate PKD signaling (by terminating activating phosphorylations). 46 We do not exclude the possibility that these alternate mechanisms could contribute or that additional PKA phosphosites exist on PKD. However, the present study demonstrates that PKA-mediated phosphorylation of PKD at S427 is the principal mechanism of β-AR/ PKA inhibition of G q R/PKD signaling.
Phosphoproteomics has identified a multitude of phosphorylation sites on PKD, but only a few have known functional consequences. 22 Interestingly, the predicted PKA target sites on PKD ( Figure 5 ) included known phosphosites, such as S748 and S916. However, phosphorylation at these sites would be expected to activate rather than to inhibit PKD activity, and we did not detect PKA-dependent phosphorylation at these sites in myocyte lysates ( Figure 2B ). 33 Sites S205 and S255 were also less likely based on their known functional effects. 11, 47, 48 The most interesting candidate was the S427 site just adjacent to the pleckstrin homology domain (ie, in the position to influence pleckstrin homology-mediated protein interactions and autoinhibitory effects. Indeed, a previous study found that PKA could directly phosphorylate S427 in vitro, but to date no functional consequences (on localization or activity) had been identified. 40 Our experiments firmly establish the S427 site as a key regulatory site of PKD signaling, providing a mechanism to integrate inputs from diverse inciting stimuli: the β-AR and G q R signaling pathways. In this scenario, slight changes in PKA activity fine-tune the PKD responsiveness to other stimuli (and possibly which downstream targets are affected). Whether S427 phosphorylation is governed by other positive and negative regulators (kinases/ phosphatases) remains to be determined, but this site offers intriguing possibilities for modulation of PKD function and cellular phenotype during the pathogenesis of cardiac disease.
Considering the effect of β-AR signaling in the fight-or-flight response and its maladaptive changes in heart failure, the PKAdependent modulation of PKD signaling efficiency and specificity is likely to have a prominent pathophysiological role. Clearly, additional experiments are needed detailing the (β-AR dependent) modulation of the S427 site versus alterations in spatiotemporal regulation and function of PKD during different stages of heart failure development. β1-AR desensitization and attenuation of its downstream signaling could reverse the negative modulation of PKD, contributing to the enhanced PKD activity observed in heart failure. 18 Other factors, such as AKAP expression, could influence the topography of PKD signaling (in time and space) in heart failure. Topographical analysis of PKD activity will be a key to unraveling the subcellular mechanisms that drive PKD dysfunction in cardiac disease.
In conclusion, we used a fluorescence-centered approach to profile spatial and temporal changes in PKD activation in response to β-AR signaling. This allowed us to visualize local nuclear PKD signaling, undetectable in global PKD measurements. This approach also revealed that the hampered Figure 7 . Working hypothesis of β-Adrenergic receptor/protein kinase A (PKA) modulation of PKD signaling. For a first pool of PKD, β-AR/PKA activation triggers nuclear PKD activity by facilitating activation of PKD at an A-kinase anchoring protein (AKAP) scaffold (cyan circle indicates activated PKD). For a second pool of PKD, β-AR/PKA activation prevents G q -coupled receptor (G q R)-dependent PKD activation and translocation primarily by PKA-dependent phosphorylation of PKD at S427E. We do not exclude that additional mechanisms (such as phospholipase C [PLC] inhibition or PP2A activation) could contribute to this inhibitory effect of PKA. AC indicates adenylyl cyclase; DAG, diacylglycerol; PE, phenylephrine; PIP2, phosphatidylinositol 4,5-bisphosphate; PLC, phospholipase C; and PP2A, protein phosphatase 2.
G q R-induced PKD activation after β-AR stimulation is because of profound perturbations in PKD translocation. PKAdependent phosphorylation of PKD-S427 was found to mediate the perturbation of G q R-induced PKD translocation and function. These findings emphasize the importance of stimuli integration and spatial segregation of PKD in achieving signaling specificity for such a multifunctional kinase. Future studies examining how desensitized β-AR signaling in heart failure contributes to PKD dysregulation will clarify the role of PKD in cardiac pathophysiology and its potential as a therapeutic target.
